Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 3Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 13Nivolumab 6Cyclophosphamide 6Carboplatin 6Specimen Handling 5Pemetrexed 5Paclitaxel 5Docetaxel 5Cisplatin 5Cetuximab 5Bevacizumab 5fludarabine phosphate 4fludarabine 4atezolizumab 4tislelizumab 3durvalumab 3Standard of Care 3Practice Guidelines as Topic 3Methods 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Gemcitabine 3Educational Status 3Early Intervention, Educational 3130-nm albumin-bound paclitaxel 3venetoclax 2tremelimumab 2temsirolimus 2niraparib 2ixazomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × 2C4 antibody × 30 days × Clear all
NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
190 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡